The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

The project, launched in June 2024 and set for full operation in mid-2026, has received strong backing from local authorities ...

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage performance of its anti-TIGIT antibody belrestotug.

JP Morgan reported in their recent outlook piece that "The backdrop for the European consumer is also improving. Real wages ...

Like going to the supermarket and staring at aisles of cereal and sauces, the average ChatGPT user is currently faced with an ...

Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...